The results were presented at a symposium during the American Diabetes Association's 84th Scientific Sessions in Orlando, Florida, and mark the first large-scale trial specifically designed to investigate the effect of fenofibrate on eye outcomes in people with early diabetic retinopathy.
Read More
Study: Repurposed drug may help stabilize vision in rare disease
June 23rd 2024Researchers at Washington University School of Medicine in St. Louis for years have worked to understand the rare condition known as retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations.
Read More
Study examines risk of open angle glaucoma in young adults with allergic diseases
June 22nd 2024A team of Korean researchers has examined data from the Korean National Health Information Database to determine whether subjects with allergic diseases exhibited a higher incidence of primary open-angle glaucoma compared to a control group.
Read More
Study examines how topical naltrexone restores tear production in diabetic dry eye
June 20th 2024Researchers found that blocking the interaction between peptide and receptor using topical applications of naltrexone reverses dry eye symptoms in 5 days and restores tear fluid volumes to normal baseline.
Read More
Ocular Therapeutix updates on clinical developments and future plans for Axpaxli
Published: June 14th 2024 | Updated: June 14th 2024The company highlighted successful enrollment in the SOL-1 Phase 3 trial for wet AMD, plans for a new repeat dosing study (SOL-R), and positive 48-week data from the Phase 1 HELIOS study for NPDR
Read More
Beacon Therapeutics treats first patient in VISTA registrational trial for AGTC-501
June 12th 2024VISTA is a global randomly assigned, controlled, masked, multi-center pivotal study evaluating the efficacy, safety, and tolerability of 2 dose levels of AGTC-501 for the treatment of X-linked retinitis pigmentosa
Read More
Pegcetacoplan injection preserves visual function at 36 weeks in patients with geographic atrophy
June 11th 2024Positive data from the GALE long-term extension study showed patients developed fewer new scotomatous points with 36 months of both continuous monthly and every-other-month treatment.
Read More
Injection-free subgroup results demonstrated that a single intravitreal dose of 4D-150 without any supplemental anti-VEGF injections resulted in stable mean visual acuity that was equal to or higher than the standard bimonthly aflibercept control group at all 6 time points through Week 24.
Read More
IOP outcomes with intravitreal injection of aflibercept, 8mg and 2mg in patients with DME
June 3rd 2024Mark Barakat, MD, sat down with Ophthalmology Times to discuss intraocular pressure outcomes with intravitreal injection of aflibercept, 8mg and 2mg in patients with diabetic macular edema through week 48 of the phase 2/3 PHOTON trial.
Read More
A post hoc analysis of the phase 2/3 PHOTON trial
June 2nd 2024Sean Adrean, MD, FAAO, sat down with Ophthalmology Times to discuss a post hoc analysis of the phase 2/3 PHOTON trial and the outcomes of patients with DME and baseline BCVA of 20/50 or worse or 20/40 or better who were treated with aflibercept 8 mg and 2 mg.
Read More